A CD-19-specific CAR-NK cells phase I/II clinical trial involving eleven patients with relapsed/refractory(R/R) CD19-positive cancers (NHL or CLL) showed no cytokine release syndrome, neurotoxicity or GvHD. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.